George Deeb, MD

PrintE-mail
Assistant Professor
Department of Pathology & Laboratory Medicine
Associate Director, Laboratory of Clinical Flow Cytometry
Roswell Park Cancer Institute
Assistant Professor of Pathology
School of Medicine and Biomedical Sciences, State University of New York at Buffalo

Profile

Areas of Expertise: 
Hematopathology

Research

Research Interests: 
Genetic and immunophenotypic markers for diagnosis, classification, and predicting prognosis of hematologic malignancies

Background Information

Education and Training: 
MD - University of Damascus Faculty of Medicine, Damascus, Syria
Residency: 
State University of New York at Buffalo
Fellowships: 
University of Wisconsin Hospitals & Clinics, Madison, WI
Roswell Park Cancer Institute, Buffalo, NY

Publications

Publications: 
  • Nowak NJ, Wang ES, Wallace PK, Ford L, Liu S, Gaile D, Deeb G, Zeidan A, Sait SNJ, Wetzler M. Recurrent deletion of 9q34 in adult normal karyotype precursor B-cell acute lymphoblastic leukemia. Cancer genetics and cytogenetics 2010; 199(1):15-20
  • Sher T, Miller KC, Deeb G, Lee K, Chanan-Khan A. Plasma cell leukaemia and other aggressive plasma cell malignancies. British journal of haematology 2010; 150(4):418-427
  • , Nowak NJ, Wetzler M, Ford LA, Starostik P, Mashtare T, Gold D, Sait SNJ, Wang ES, Deeb G. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse. Cancer genetics and cytogenetics 2010; 202(2):101-107
  • Malik DA , Starostik P , Deeb G , Risch N, Barcos M , Merzianu M. Comparative assessment of zinc-based fixatives in hematopathology practice. American journal of clinical pathology 2010; 134(4):58
  • Advani P, Ngamphaiboon N, Pukiat S, Chavez J, Deeb G, Elefante A, Hernandez-Ilizaliturri FJ. The expression of bcl-6 in diffuse large B cell lymphoma (DLBCL) is associated with improved progression free survival and overall survival following front-line rituximab-chemotherapy. Blood 2010; 116(21):5073
  • Barth M, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs J, Deeb G, Czuczman MS. Ofatumumab, a fully human monoclonal antibody targeting CD20, demonstrates activity against and potentiates the anti-tumor activity of chemotherapy agents in rituximab-sensitive cell lines (RSCL), rituximab-resistant cell lines (RRCL), lymphoma xenografts, and primary tumor cells derived from patients with B-cell non-hodgkin lymphoma (NHL). Blood 2010; 116(21):3917
  • Derby L, Pendurti G, Deeb G, Sait S, Block A, Hernandez-Ilizaliturri FJ. Blastoid variant of mantle cell lymphoma (MCL) is associated with P53 abnormalities and have a shorter progression-free survival (PFS) and overall survival (OS) despite upfront chemo-immunotherapy followed by high dose chemotherapy and autologous stem cell support (HDC-ASCS). Blood 2010; 116(21):1773
  • Gu J, Ritesh P, Mavis C, Deeb G, Gibbs J, Hernandez-Ilizaliturri FJ, Czuczman MS. MLN2238, a novel and potent proteasome inhibitor, induces caspase-dependent cell death, cell-cycle arrest, and potentiates the anti-tumor activity of chemotherapy agents in rituximab-chemotherapy sensitive or resistant B-cell lymphoma cell lines. Blood 2010; 116(21):3939
  • Pukiat S, Ngamphaiboon N, Advani P, Chavez J, Deeb G, Elefante A, Hernandez-Ilizaliturri FJ. BCL-2 expression at the time of diagnosis affects the clinical outcome of patients with germinal center and non-germinal center diffuse large B-cell lymphoma (DLBCL) treated with chemo-immunotherpy. Blood 2010; 116(21):3130
  • Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, Witzig TE, Goy A, Czuczman MS. Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with nongerminal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R). Journal of clinical oncology 2010; 28(15 Suppl.):8038
  • Block AW, Thompson JE, Wang ES, Starostik P, Deeb G, Sait SN, Ford L, Wilding GE, Groman AE, Wetzler M. The role of FLT3 in sole trisomy 8 acute myeloid leukemia. Journal of clinical oncology 2010; 28(15 Suppl.):6562
  • Bharthuar A, Egloff L, Becker J, George M, Lohr JW, Deeb G, Iyer RV. Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report. Cancer chemotherapy and pharmacology 2009; 64(1):177-181
  • Khuhchandani S, McCarthy PL, Cheney R, Hahn T, Syta M, Brown K, Paplham P, Battiwalla M, Smiley SL, Deeb G, Hong F. Fatal hyperacute graft-versus-host disease following denileukin diftitox treatment for recurrent t cell lymphoma after allogeneic stem cell transplantation. Biology of blood and marrow transplantation 2009; 15(7):887-890
  • Brem EA, Czuczman MS, Fetterly G, Gibbs JF, Deeb G, Hoskin P, Mavis C, Knight J, Campagna R, Iqbal A, Gu J, Riaz W, Bhat S, Olejniczak SH, Tsai PC, Khubchandani S, Thudium K, Hernandez-Ilizaliturri FJ. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. British journal of haematology 2011; 153(5):599-611
  • Deeb G, Vaughan MM, McInnis I, Ford LA, Sait SN, Starostik P, Wetzler M, Mashtare T, Wang ES. Hypoxia-inducible factor-1alpha protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leukemia research 2011; 35(5):579-584
  • Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. British journal of haematology 2008; 140(1):36-45
  • Cruz RI, Hernandez-Ilizaliturri FJ, Olejniczak S, Deeb G, Knight J, Wallace P, Thurberg BL, Kennedy W, Czuczman MS. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leukemia and lymphoma 2007; 48(12):2424-2436
  • Demock KM, Marinaro J, McInnis I, Ford LA, Wetzler M, Tian L, Deeb G, Wang ES. Hypoxia-Inducible Factor-1 Alpha (HIF-1 alpha) and HIF-2 alpha Are Independent Prognostic Factors for Normal Karyotype Acute Myeloid Leukemia (NK AML). Blood 2008; 112(11):887
  • Demock KM, Marinaro J, Sobczyk A, Ford LA, Wetzler M, Deeb G, Tian L, Wang ES. Expression of Vascular Endothelial Growth Factor Receptors VEGFR-1 and VEGFR-2 Are Prognostic Factors in Normal Karyotype Acute Myeloid Leukemia (NK-AML). Blood 2008; 112(11):886-887
  • McInnis I, Hahn T, Ioane A, Larnson A, Lal D, Ford LA, Sait SNJ, Starostik P, Deeb G, Wetzler M, Mashtare T, Wang ES. Diverse Roles of Hepatocyte Growth Factor (HGF) in Normal Karyotype Acute Myeloid Leukemia (AML). Blood 2009; 114(22):1208
  • Reddy NM, Hernandez-Ilizaliturri F, Roth M, Vaughan M, Deeb G, Czuczman MS. Lenalidomide enhances rituximab anti-tumor activity by inducing expansion, activation and tumor infiltration of Natural killer (NK) cells, as well as alters the tumor microenvironment and inhibits angiogenesis. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:844-845
  • Wang ES, Sobczyk A, Marinaro JM, Wetzler M, Tian L, Deeb G. VEGF-A, VEGF-C, and CD31 expression by leukemia cells are prognostic factors for overall survival in acute myeloid leukemia (AML). Blood 2007; 110(11 Part 1):Abstract #2392
  • Zeidan A, Gaile D, Conroy JM, McQuaid DE, Wang ES, Deeb G, Wallace PK, Sait SNJ, Nowak NJ, Wetzler M. Frequent molecular aberrations in normal karyotype (NC) precursor B-cell acute lymphoblastic leukemia (pB-ALL) detected by comparative genomic hybridization. Blood 2007; 110(11 Part 2):135B (Abstract #4270)
  • Smonskey M, Starostik P, Deeb G, Demock K, Vargas R, Lal D, Sait SN, Wetzler M, Wang ES. Association of IDH1 mutations in normal karyotype acute myeloid leukemia samples with higher HIF-1{alpha} and VEGF-A expression : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):6530
  • Gruber TJ, Fabiano AJ, Deeb G, Lele SB, Fenstermaker RA. Intracranial meningiomas in patients with uterine sarcoma treated with long-term megestrol acetate therapy. World neurosurgery 2011; 76(5):477.e16-477.e20
  • Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, MacOn WR, Goy A, Witzig TE, Czuczman MS. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011; 117(22):5058-5066
  • Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, Czuczman MS. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. British journal of haematology 2012; 156(4):490-498
  • Smonskey MT, Block AW, Deeb G, Chanan-Khan AA, Bernstein ZP, Miller KC, Wallace PK, Starostik P. Monoallelic and Biallelic Deletions of 13q14.3 in Chronic Lymphocytic Leukemia: FISH vs miRNA RT-qPCR Detection. American journal of clinical pathology 2012; 137(4):641-646
  • Sardesai SD, Tan W, Ford LA, Deeb G, Block AMW, Sait SNJ, McCarthy PL, Vigil CE, Griffiths EA, Thompson JE, Wang ES, Wallace PK, Wetzler M. Predicting outcome based on minimal residual disease (MRD) using multiparameter flow cytometry (FC) in acute myeloid leukemia (AML) patients (Pts) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #6565